State Street’s Scribe Therapeutics Inc SCTX Stock Holding History

State Street’s Portfolio SCTX Stock Details SCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.15M	Buy	+171,147	New	+$4.51M	﹤0.01%	3260

Other funds holding SCTX

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Menlo Ventures Management Menlo Park, California $241M AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

State Street's SCTX Position: Q3 2026 in Review

State Street opened a new position in Scribe Therapeutics Inc (SCTX) in Q3 2026: 171,147 shares worth $3.15M. The stake represents ﹤0.01% of the portfolio and ranks #3260 among its holdings.

23 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

State Street held 171,147 shares of Scribe Therapeutics Inc worth $3.15M as of Q3 2026.
Scribe Therapeutics Inc was a new State Street position in Q3 2026.
Scribe Therapeutics Inc made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3260 holding.
23 funds tracked by Wall St. Rank held Scribe Therapeutics Inc as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.